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SUMMARY
The post-trial access to investigational drugs has been the object of discussion since the 
late 1980s at least, initially linked to trials carried out in acquired immunodeficiency 
syndrome and, particularly, in developing countries, where the concern with patient 
vulnerability is more important. National and international guidelines do mention the 
subject; however, the complexity of the issue is not easily addressed and usually requires 
additional and specific discussions. The decision on providing the investigational drug 
after the trial shall rest on at least two dimensions: efficacy and safety assessments, as the 
new drug is still on the experimental phase. Each clinical trial shall have its own assess-
ment, taking into account the disease being studied, as well as the study population and 
their specific needs. Therefore, the nature of post-trial obligations cannot be considered 
the same in all situations and contexts; nevertheless, it should be assured that the rela-
tionship developed between investigators and patients during the study must be always 
terminated with respect and responsibility.
Keywords: Continuity of patient care; drugs, investigational; clinical research; bioethics; 
ethics committees, research; vulnerability.  
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The globalization of clinical trials, observed in recent 
years, brought up new issues and the continuity of treat-
ment that includes the drug under investigation, after 
research completion, is one of them. The subject can 
be seen on the pages of scientific journals since the late 
1980s, particularly associated with continuing treatment 
in patients who participated in studies on HIV (human 
immunodeficiency virus) and/or AIDS (acquired immu-
nodeficiency syndrome). The continuity of medical care, 
including treatment, is based on the ethical responsibil-
ity to compensate individuals who voluntarily agreed to 
participate in the research for the development of science, 
and were exposed to unknown risks, additional invasive 
procedures, questions about their habits and personal life, 
among others.
Additionally, the research participants may not have, 
after the study conclusion, access to the drug in the health-
care service of their country or even the medical care they 
need1. This concern is certainly greater in developing 
countries, as the research participants (and the population 
itself) are particularly vulnerable as a result of poverty, il-
literacy, limited resources, insufficient access to healthcare, 
and lack of familiarity with clinical research2. 
INTERNATIONAL GUIDELINES 
National and international documents refer to the subject 
of post-trial access to the investigational drug. The Decla-
ration of Helsinki, accepted and recognized worldwide as a 
reference document on biomedical ethics (World Medical 
Association, WMA, 1964), incorporated the subject relat-
ed to post-research obligations3 only in the review carried 
out in 2000, stating that “at the end of the study, all partici-
pants must have guaranteed access to the best proven pro-
phylactic, diagnostic and therapeutic methods identified 
by the study”. A note of clarification issued by the WMA in 
2004, added: “it is necessary, during the study planning, to 
identify ways to ensure the procedures identified as benefi-
cial in the study or access to other appropriate care.” 
In the sixth review of the Declaration (Korea, 2008), 
the issue was revisited and, since then, the new text in-
clude, in paragraphs 14 and 33, respectively: “the proto-
col must describe post-study agreements so that the re-
search subjects have access to interventions identified as 
beneficial in the study or access to other appropriate care 
or benefits” and “at the study conclusion, patients includ-
ed in it have the right to be informed about the results 
and share the benefits of the study, for instance, access to 
interventions identified in the study as beneficial or other 
appropriate care”4. 
Another important international guideline is the 
Council for International Organizations of Medical Sci-
ences (CIOMS), a non-governmental, non-profit organi-
zation created in 1949 by the World Health Organization 
(WHO) and the United Nations Educational, Scientific 
and Cultural Organization (UNESCO)5. In its 1993 publi-
cation, it mentions that the product under study should be 
“reasonably available” to the country or the inhabitants of 
the community that hosted the study and that exceptions 
should be justified and agreed by all concerned before the 
start of the study. This text was also reviewed in 2002: “the 
sponsor and the investigator shall make every effort to en-
sure that any intervention or product developed or knowl-
edge generated, is made reasonably available for the ben-
efit of the population or community”5,6. The Declaration 
points out that the post-trial access is a benefit only to the 
research subjects, while the CIOMS extends this group to 
also include the community or population. In dealing with 
the documentation on post-trial availability, the Declara-
tion proposes that the preparations for post-trial access 
should be documented in the research protocol, while the 
CIOMS demands that they be incorporated into the Free 
and Informed Consent Form3.  
The WHO published, in 2000, the “Operational 
Guidelines for Ethics Committees that Review Biomedi-
cal Research”. When dealing with recruitment of patients 
in clinical studies (item 6.2.6.6), the need for “a descrip-
tion of the availability and affordability of any successful 
study product to the concerned communities, following 
the research” is mentioned5. 
Other commonly cited guidelines are those of the 
Nuffield Council on Bioethics7 and the National Bioeth-
ics Advisory Commission (NBAC)8 of 2001 and 2003, 
respectively. In dealing with the sponsors’ responsibil-
ity, the first document emphasizes that researchers must 
commit, before starting a trial, to ensure that upon com-
pletion, participants will have access to effective inter-
ventions. However, it also recognizes that access provi-
sion will depend on several factors, such as availability 
of alternatives, the threat that the disease brings and the 
cost of providing the drug(s) and that the responsibil-
ity of making a successful intervention available is, pri-
marily, of governments7. The NBAC recommends that 
research projects must include an explanation on how 
new interventions will be made available to some or all 
the populations of the countries that are hosting the re-
search, in addition to the study volunteers themselves, 
when they are proven to be effective, after the research8.
Finally, the Universal Declaration on Bioethics and 
Human Rights (UNESCO, 2005), signed by 191 coun-
tries, including Brazil, quotes (Art. 15): “benefits re-
sulting from any scientific research and its applications 
should be shared with society as a whole and within the 
international community, in particular with developing 
countries”. The “benefits”, however, can take many forms, 
consistent with the principles of the Declaration, not nec-
essarily continuity of treatment9. 
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NATIONAL GUIDELINES 
In Brazil, the reference document in biomedical research 
is Resolution 196, published by the Conselho Nacional 
de Saúde – National Health Council (CNS), in 199610. It 
depicts, in several paragraphs, quotes that make direct 
or indirect reference to the issue of post-trial drug access 
(III.3m): “ensure that research carried out in communities, 
wherever possible, will translate into benefits of which ef-
fects will continue to be felt after its completion”; (III.3n) 
“ensure the return of benefits gained through researches 
to individuals and the communities in which they are 
carried out”; (III.3p) “to ensure the research subjects will 
receive the benefits resulting from the project, either in 
terms of social return, access to procedures, products or 
investigation agents”; (V.3) “as soon as the superiority of 
one method undergoing investigation over another is es-
tablished, the project should be suspended, and all subjects 
must be offered the benefits of the best regimen”; (VI.3h) 
“present estimates of reimbursements to research subjects; 
the amount cannot be such that it may interfere with the 
autonomy of the individual’s or the person in charge of this 
decision on whether or not participate in the research”.
Resolution 251 of the CNS, 1997, quotes the subject 
more explicitly (IV.m): “it shall be ensured by the sponsor 
or, if it does not exist, by the institution, investigator or 
promoter, access to drug under test, should it be proven to 
be superior over the conventional treatment”11. 
Considering that the Declaration of Helsinki was un-
der review, the CNS published Resolution 404 in Septem-
ber 2008: “considering the responsibility of the CNS to 
protect the integrity of research subjects and the several 
existing national and international guidelines, all partici-
pating patients must have guaranteed access to the best 
methods identified by the study, preserving the 2000 ver-
sion of the Declaration of Helsinki”12.
AVAILABLE LITERATURE: ORIGINAL ARTICLES AND REVIEWS
There are few published studies on post-trial drug access 
and the existing ones are mostly on HIV/AIDS, where the 
subject was born. 
A survey carried out in developing countries, with re-
searchers in the HIV/AIDS field, concluded that the patient 
population of the studies should benefit from the study, and 
more than half of the professionals surveyed said that the in-
terventions (HIV drugs) should be provided to the research 
population after the study, for a year or more13.
A study carried out through interviews with presidents 
and members of research ethics comittees (RECs), as well 
as researchers and research participants, evaluated the 
ethical aspects related to conducting clinical trials outside 
the United States. Sixty-five of 94 questionnaires sent to 
members of RECs returned, as well as 117 of 159 sent 
to researchers and 359 of 510 sent to research participants. 
Eighty-three percent of research participants (of which 
43% were from Latin America, Brazil included), 29% of 
RECs members and 42% of researchers said the drugs 
should be provided for all infected people worldwide, if 
proven beneficial. Most research participants from Europe 
and Latin America said that the drug should be continued, 
while those from North America, Australia and Thailand 
said that the drug should be made available at a price that 
a middle-class individual could buy14.  
A qualitative study, carried out through focal groups in 
Kenya, with 89 subjects (potential patients for HIV/AIDS 
studies, researchers and administrators) has brought, as 
conclusion, that it would not be reasonable to discontinue 
therapy after studies in HIV/AIDS patients, except in  fully 
justified cases15.
A systematic review of clinical studies enrolled in in-
ternational registries, from 2004 to 2007, was carried out 
by Cohen et al.16 involving HIV/AIDS, malaria and tuber-
culosis. Of the 312 studies that were included, the majority 
in developed countries (56%), with 28% being sponsored 
by pharmaceutical companies, only 4 (1.3%) mentioned 
post-study provisions: one mentioned the post-study drug 
would be provided by the governments of the respective 
countries; another, that the participants who became in-
fected with HIV during the study would receive counsel-
ing and education about the infection/disease and access 
to necessary healthcare, including free-of-charge antiret-
roviral drugs, if indicated. 
In 2008, Zong17 published an article discussing the 
issue of post-trial continuity of care, citing the main in-
ternational guidelines and recommendations about the 
subject, including Resolution 196/96 of the CNS. After 
careful reflection, the author suggests collaborative part-
nership between the various participants in the research 
scenario: the REC (by approving the conditions of drug 
provision after the research), the sponsor (by organizing 
the drug provision), the local health system (by distribut-
ing and monitoring patients), researchers, and finally, the 
patients, by following the appropriate rules of provision, 
regular attendance at follow-up visits and adequate report-
ing of possible adverse events. 
Ciaranello et al.18 published in 2009, a systematic re-
view of protocols and informed consents for phase III and 
IV clinical trials with ART, carried out between 1987 
and 2006. Studies were selected from www.clinicaltrials.
gov and from the AIDS Clinical Trials Group (ACTG) 
registry, with the purpose of analyzing the reference to 
post-trial services. Thirty-one studies met the inclusion 
criteria: 14 (45%) trials mentioned some post-trial service: 
12 (39%) mentioned the study drugs (10 of them offered 
the test drug) and 5 (16%) mentioned healthcare servic-
es. Of the 10 studies that offered the medication after the 
study, 8 did so with sponsorship from industry; 6 offered 
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the drug to all study participants until it became available 
commercially, or for a defined period, and 2 of them only 
to patients who completed the study in the experimental 
arm. This diversity of actions reflects the differences in in-
terpretation of the current guidelines. 
Sofaer et al.19 described the opinion of 93 individu-
als who participated in clinical trials in chronic diseases 
in the United States. In this study, patients were divided 
into 10 focal groups. Many participants felt that research-
ers, sponsors and insurance companies should share the 
post-trial obligations. Others commented that no care or 
drug should be necessary after the research, but there was 
an almost general agreement that patients should receive 
information about the study and its results. The authors 
conclude by suggesting that the debate on post-trial obli-
gations must go beyond the issue of the test drug. 
Barsdof et al.20, in a study published in 2010, assessed 
the viewpoints of a community in South Africa regard-
ing the provision of HIV vaccines, after participating in 
research on contamination prevention: 29 adults par-
ticipated in depth interviews. According to them, re-
searchers should help patients have access to treatments 
and healthcare because “they are in a position to do that” and 
because “they have a relationship with the research par-
ticipants”.
A study published by Shah et al.21, in 2009, assessed 
whether the NIH guidelines have been established in stud-
ies sponsored by it in developing countries. The 18 studies 
identified in the database of the Division of AIDS (DAIDS) 
contained access plans after the research: more than 70% 
(13 of 18) had specific mechanisms for that, but none of 
them guaranteed long-term access. All but one study dis-
cussed the post-study topic in the protocol or informed 
consent. The study that did not do it, addressed the issue 
in letters sent to the DAIDS. Half of the included studies 
contained descriptions of post-study access that included 
collaboration with outside sources or national access pro-
grams, created by the governments of the countries hosting 
the researches. None of the studies stated that the research 
participants would receive priority access in relation to 
other patients in the country. The authors conclude that 
the strength and shape of the NIH guidelines encourage 
researchers to seek alternatives and collaboration to facili-
tate access to the required treatment. At the same time, the 
flexibility of the guidelines facilitates and encourages 
the learning of practical difficulties, a more effective strat-
egy than imposing requirements that researchers may be 
unable to meet21. 
The NIH has enlightening guidelines on various as-
pects of this theme. For instance, one of the questions cov-
ered by the Questions and Answers (Q&A) session is why 
the NIH itself does not provide antiretroviral treatment 
after completion of the study carried out by themselves22. 
The answer is the justification that the NIH is statutorily 
authorized to conduct and support biomedical research. 
In this context, it cannot give support or provide medicinal 
products outside the research situation. Still, it acknowl-
edges the need to assess alternatives for continuing treat-
ment after the study. It also explains why the policy applies 
only to the area of  HIV/AIDS, and only for developing 
countries, where the discontinuity of treatment could have 
tragic consequences, including increased risk of mortality. 
When the study includes research centers inside and out-
side the United States, the guideline applies only to those 
outside the country.
Thus, it can be observed an additional concern with 
patients from other countries, unlike what is usually seen 
when criticisms are made  to the “unethical” conduct of 
international multicenter studies in countries of lower 
income. The answer to the question: “Does the treatment 
after the study have to be the same regimen used during 
the research?” clarifies that the purpose of the guideline is 
to ensure that patients continue to receive effective treat-
ment after the study, but not specifically a particular type 
of treatment. Treatment should be determined based on 
individual medical needs, on what is available in the coun-
try, and the scientific progress in the study field. 
In Brazil, Cabral et al.23 address the issue of post-trial 
provision also with predominant focus on studies in the 
area of  HIV/AIDS. In the article, the authors comment 
that making the research product reasonably accessible is 
not enough to prevent the exploitation of the participant, 
in most cases. According to them, when the research is of 
high risk for the individual, this principle is not sufficient 
to ensure non-exploitation.
One usually speaks only of benefits to patients, put-
ting aside the important concern that must be considered 
regarding the potential risks of a product not yet fully 
studied24. Falit & Gross25 discuss the question of the risks 
involved and of patient protection, in an article from 2008 
about terminally ill patients’ access to experimental drugs, 
highlighting the importance of minimizing damage, seek-
ing balance in the selection of appropriate treatment for 
these patients. 
Lacativa et al.26 published in 2008, the result of a cross-
sectional study in an outpatient research center, in Rio de 
Janeiro, in which a questionnaire was used to assess how 
patients perceived their participation in research at that 
center, and what motivated them to participate. One of the 
questions specifically investigated why patients agreed to 
participate. Fifty-nine percent answered that the main mo-
tive was to learn more about their own health and 47% said 
it was for the benefit of others in the future. Lack of or dif-
ficulty to obtain medical care in their city was mentioned 
by 21% of respondents; to receive free medication and ex-
aminations was mentioned by only 16% of interviewees. 
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In 2007 and 2008, three review articles on the subject 
were published in Brazil on the themes presented here, pro-
posing some solutions and at the same time, stimulating 
debate and acknowledging this discussion as new and still 
controversial, within the environment of the national and 
international ethics3,27,28. 
A recent work carried out as a doctoral thesis evaluated 
the views of the key stakeholders on the continuing provi-
sion of drugs after the completion of clinical trials (clinical 
researchers, REC members, sponsors and patients) through 
an internet survey. Questionnaires and the respective In-
formed Consent Forms were sent by e-mail, between Oc-
tober 2009 and January 2010, to REC members (all RECs 
registered with CONEP by that date), researchers (in two 
therapeutic areas, HIV/AIDS and diabetes mellitus) and 
sponsors. Researchers were asked to apply the questionnaire 
to their research patients. The response rate of RECs was 
20.7% (124 responses of 599 questionnaires), 20% for the 
researchers (58 of 290) and 45.3% for the sponsors (24 of 
53). Fifty-four patients invited by their doctors answered it. 
With respect to information contained in the consent form, 
the item that contained the least information was how to 
obtain the drug after the study, for all groups surveyed.
When asked about who should receive the test drug 
after the study, patients and the RECs answered that ev-
eryone should receive the drug after the study (respec-
tively 60.4 and 35.3%); among researchers, most (43.1%) 
answered that the drug should be provided to people par-
ticipating in the study and 39.7% of them answered that the 
drug should be given to people who would benefit from 
the study medication. The sponsors felt that the study drug 
should be given to research participants who would benefit 
from it (50%). 
There was a consensus among groups regarding that, 
with continuing treatment, this should be provided by the 
sponsor and for free. When answering the question of for 
how long the drug should be provided, researchers and 
sponsors considered that the drug should be provided un-
til it would be available to the public, while REC members 
stated that provision should continue while there were ben-
efits to the patient. The patients responded that the benefit 
should be maintained for life. Due to the limitations of this 
study (sample representativeness, population restricted to 
internet users), its results cannot be generalized, but con-
tribute to the views of various participants in the national 
clinical research scenario29. 
A Master’s Degree dissertation submitted in 2009 also 
assessed the issue of drug provision after research, inter-
viewing 25 professionals from the pharmaceutical industry 
and Clinical Research Organizations (CROs). It was ob-
served that patients with severe and life-threatening illness-
es are not neglected and always receive the medication after 
the end of the study. The author comments that the existing 
legislation in Brazil was not sufficiently comprehensive for 
all situations and that CONEP kept an uncompromising 
stance against the request of post-study drug provision, re-
gardless of the type of research and patients’ needs30.
A work published by researchers in the field of oncolo-
gy at Duke University in 2010, assessed the implications of 
“off-protocol” treatments in relation to patient safety, access 
to healthcare and inclusion in clinical trials31. In this work, 
172 phase-III studies were selected according to criteria 
defined by the authors. Although 47% of the experimental 
interventions proved to be superior in at least one major 
clinical outcome, only 27% of them showed improvement 
in relation to survival. In about two thirds of randomized 
clinical trials, at least a greater toxicity was observed in the 
experimental arm when compared to standard therapy. 
Additionally, although in most clinical studies the out-
comes were at least comparable between the two groups, in 
11 randomized trials, patients in the experimental arm got 
worse. These are potential consequences of experimental 
treatments outside the research protocols. 
A meeting promoted by CONEP in 2009 led to the 
discussion of post-trial access issue, with the contribution 
of various participants in the clinical research scenario32. 
It was clear, for instance, that effectiveness cannot always 
be ensured immediately after study completion and, in 
phase-III double-blind studies, at the end of the study, 
it is yet unknown which medication each patient is re-
ceiving and to break the randomization code implies in 
protocol violation. At this time, ANVISA reaffirmed that 
the drug provision as an extension of the study would 
be the ideal process, as the patient would receive follow-
up according to the protocol, in a (still) controlled re-
search environment. CONEP did not agree with changing 
the text regarding the norms, suggesting the maintenance 
of the access request as a general rule, while there is ben-
efit to the patient.
At the start of a clinical trial, the physician becomes the 
investigator, the patient, formerly treated in care, becomes 
the research subject and treatment becomes an investiga-
tional drug, according to the research protocol. In this con-
text, the research protocol is simply part of the formation of 
scientific evidence, and thus differs from the final evidence, 
consisting of a set of studies and publications that can be 
transformed into guidelines and consensuses. Additionally, 
the patient is the focus of treatment in medical assistance 
and in clinical research, it is the drug29.
   
CONFLICTING LEGISLATION POINTS
The analysis of post-trial access issue, from the legal point 
of view, shows difficulties and even prohibitions, when 
attempting to enable medication donation. Article 12 of 
Law 6360, of 1976, for instance, cites: “none of the prod-
ucts mentioned in this Law, including imported ones, can 
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be industrialized, exposed for sale or delivered to the con-
sumer before it is registered with the Ministry of Health”33. 
The only exception to this rule is the use of experimen-
tal drugs in clinical trials, controlled by the physician in 
charge and approved by ANVISA, limited to three years, 
after which the drug will be subject to confiscation, in ac-
cordance with Article 24 of Law 636033. 
Interestingly, although addressing the same theme – 
experimental drug use – the Collegiate Board Resolutions 
(RDCs) of ANVISA and the CNS do not mention the same 
decrees and laws in their initial “considerations”. Law 6360, 
for instance, which deals with health surveillance to which 
drugs, pharmaceutical raw materials, etc. are subject, is 
cited in all RDCs of ANVISA, but in none of CNS resolu-
tions. As for the CNS resolutions, they usually cite Decree 
#99438 of 1990 (organization and competences of the Na-
tional Health Council), the Organic Health Law 8080 of 
1990 (on the conditions of healthcare, organization and 
operation of services), Law 8142 of 1990 (on the participa-
tion of the community regarding the management of the 
Brazilian Public Health System - SUS) and Decree 5839 of 
2006 (on the organization, competences and election pro-
cesses of the National Health Council)34. 
In general, the laws mentioned in the resolutions, de-
crees or legislative acts are those that empower the authori-
ties to regulate on the subject or deal with the matter to be 
regulated. Thus, the laws that created and established the 
powers of the CNS and ANVISA are distinct: the CNS has 
an advisory nature only and should work with public health 
policies, only. ANVISA deals with product registration and 
sanitary surveillance. Although both protect the same asset 
(health), one agency might eventually recommend some-
thing that is practically impossible for the other. 
CONCLUSION
The investigational drug continuity after the clinical re-
search is necessary in some situations, but may not be ap-
propriate in others. The decision must be submitted to at 
least two assessments: efficacy and safety of the new ex-
perimental drug. And possibly, the solution is not going to 
be either sole or simple; each clinical study must have its 
own assessment, with its specificities, as every disease has 
its own characteristics and each population has specific 
needs. The nature of post-trial obligations, therefore, can 
not be considered the same in all situations and contexts; 
however, the relationship created between researchers and 
patients during a clinical trial should always be terminated 
with responsibility and respect. 
First, one should consider and reflect upon the differ-
ences between the locations where the research is carried 
out and the available health area resources. Instead of de-
nying or limiting the participation of patients and commu-
nities that can benefit from the research, the interaction 
between the various participants and sectors is strongly 
recommended. Second, to require agreements made prior 
to the start of the research, one is encouraged to build col-
laborative partnerships between sponsors, whether they 
are public or private, researchers, the government and 
other organizations. And, while allowing flexibility, to en-
able the development of proposals so that access can be 
guaranteed in the long term, after the research has ended 
and not only in the period immediately following its con-
clusion. Third, to extrapolate results and experiences from 
one therapeutic area to another may not be so simple.
The primary goal of clinical research is to contribute 
to scientific knowledge and, if properly designed and con-
ducted, it is the most ethical and methodologically appro-
priate way to attain new therapeutic options. The benefits 
resulting from clinical research are, therefore, extended to 
all people, not only to the research participants.
It is also noteworthy the fact that legislation on these 
issues (RDC 26/99 on Expanded Access) is being timely 
reviewed by ANVISA, with the active participation of the 
government, sponsors (industry and CROs), researchers 
and CONEP, in order to incorporate aspects related to the 
compassionate use of experimental drugs and drug provi-
sion after the research, in addition to reviewing processes 
as a whole.
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